Floatz logo

Efbemalenograstim Alfa

Chemotherapy Induced Neutropenia

Henan Cancer HospitalPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Chemotherapy Induced Neutropenia cohort.

Asset / SponsorPhaseRating
f-627
EVIVE Biotechnology
Phase 3BBB
FILGRASTIM
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 4BBB
PEGFILGRASTIM
Affiliated Hospital of North Sichuan Medical College
Phase 4BBB
Cefepime
Hospital Universitari Vall d'Hebron Research Institute
Phase 4BB
Spi-2012
Spectrum Pharmaceuticals, Inc
Phase 3BB

View all 50 →

Same molecule, other indications

Efbemalenograstim Alfa is also rated in:

cervical cancerDormant
CCC
Indicative ·
48 / 100
View asset →
ovarian cancerDormant
CC
Indicative ·
46 / 100
View asset →
Solid Tumor CancerDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →